Vaxcyte Inc
PCVX56.150USD
+2.240+4.16%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
7.30BCap. mercado
PérdidaP/E TTM
Más Datos de Vaxcyte Inc Compañía
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Información de Vaxcyte Inc
Símbolo de cotizaciónPCVX
Nombre de la empresaVaxcyte Inc
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoPickering (Grant E)
Número de empleados414
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 12
Dirección825 Industrial Road, Ste. 300
CiudadSAN CARLOS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94070
Teléfono16508370111
Sitio Webhttps://vaxcyte.com/
Símbolo de cotizaciónPCVX
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoPickering (Grant E)
Ejecutivos de Vaxcyte Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
558.46K
-100000.00%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-7045.00%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
13.74K
-61850.00%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-5102.00%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+3041.00%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+3041.00%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.04K
+3041.00%
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
3.04K
+3041.00%
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
2.50K
+1357.00%
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
558.46K
-100000.00%
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
27.26K
-7045.00%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
13.74K
-61850.00%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
12.60K
-5102.00%
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
8.67K
+3041.00%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.67K
+3041.00%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 15 de nov
Actualizado: sáb., 15 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
9.29%
The Vanguard Group, Inc.
8.63%
RA Capital Management, LP
8.48%
Fidelity Management & Research Company LLC
7.33%
BlackRock Institutional Trust Company, N.A.
5.95%
Otro
60.32%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
9.29%
The Vanguard Group, Inc.
8.63%
RA Capital Management, LP
8.48%
Fidelity Management & Research Company LLC
7.33%
BlackRock Institutional Trust Company, N.A.
5.95%
Otro
60.32%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
40.80%
Investment Advisor/Hedge Fund
28.90%
Hedge Fund
17.96%
Venture Capital
10.55%
Research Firm
2.07%
Sovereign Wealth Fund
0.70%
Pension Fund
0.54%
Individual Investor
0.50%
Bank and Trust
0.43%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
698
144.29M
102.33%
-18.18M
2025Q3
668
148.53M
114.41%
-14.14M
2025Q2
654
150.97M
116.29%
-1.23M
2025Q1
669
149.26M
115.73%
-5.52M
2024Q4
629
143.44M
111.44%
-3.61M
2024Q3
579
138.80M
114.99%
+5.28M
2024Q2
508
125.57M
113.86%
-5.08M
2024Q1
487
122.06M
113.01%
+8.05M
2023Q4
444
106.09M
111.72%
-6.02M
2023Q3
417
110.70M
121.97%
-7.51M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
13.10M
10.01%
-1.59M
-10.80%
Sep 30, 2025
The Vanguard Group, Inc.
12.29M
9.39%
+323.37K
+2.70%
Sep 30, 2025
RA Capital Management, LP
11.97M
9.14%
--
--
Sep 30, 2025
Fidelity Management & Research Company LLC
10.34M
7.9%
+289.69K
+2.88%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
6.41%
-654.49K
-7.24%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
8.32M
6.35%
+2.31M
+38.56%
Sep 30, 2025
Wellington Management Company, LLP
5.03M
3.84%
+77.97K
+1.57%
Sep 30, 2025
State Street Investment Management (US)
4.79M
3.66%
-156.35K
-3.16%
Sep 30, 2025
D. E. Shaw & Co., L.P.
4.29M
3.28%
+1.20M
+38.93%
Sep 30, 2025
Paradigm BioCapital Advisors LP
3.78M
2.89%
+411.92K
+12.21%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Harbor Health Care ETF
4.32%
ALPS Medical Breakthroughs ETF
2.39%
State Street SPDR S&P Biotech ETF
1.65%
Direxion Daily S&P Biotech Bull 3X Shares
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
ProShares Ultra Nasdaq Biotechnology
0.58%
Invesco Nasdaq Biotechnology ETF
0.57%
iShares Biotechnology ETF
0.5%
JPMorgan Fundamental Data Science Small Core ETF
0.44%
iShares Russell 2000 Value ETF
0.34%
Ver más
Harbor Health Care ETF
Proporción4.32%
ALPS Medical Breakthroughs ETF
Proporción2.39%
State Street SPDR S&P Biotech ETF
Proporción1.65%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.89%
ProShares Ultra Nasdaq Biotechnology
Proporción0.58%
Invesco Nasdaq Biotechnology ETF
Proporción0.57%
iShares Biotechnology ETF
Proporción0.5%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.44%
iShares Russell 2000 Value ETF
Proporción0.34%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
